Agios Pharmaceuticals Inc. (AGIO)’s Financial Results Comparing With Sangamo Therapeutics Inc. (NASDAQ:SGMO)

Both Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 115.85M 24.02 348.28M -6.03 0.00
Sangamo Therapeutics Inc. 79.89M 13.91 90.30M -0.69 0.00

Table 1 highlights Agios Pharmaceuticals Inc. and Sangamo Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. -300.63% -44.1% -36.2%
Sangamo Therapeutics Inc. -113.03% -21.9% -13.8%

Volatility & Risk

Agios Pharmaceuticals Inc.’s 2.4 beta indicates that its volatility is 140.00% more volatile than that of S&P 500. From a competition point of view, Sangamo Therapeutics Inc. has a 2.81 beta which is 181.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio of Agios Pharmaceuticals Inc. is 6.6 while its Quick Ratio stands at 6.6. The Current Ratio of rival Sangamo Therapeutics Inc. is 6.3 and its Quick Ratio is has 6.3. Agios Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Sangamo Therapeutics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Agios Pharmaceuticals Inc. and Sangamo Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 2 3.00
Sangamo Therapeutics Inc. 0 1 0 2.00

Agios Pharmaceuticals Inc. has an average target price of $75, and a 58.23% upside potential. Meanwhile, Sangamo Therapeutics Inc.’s average target price is $10, while its potential upside is 3.84%. Based on the analysts belief we can conclude, Agios Pharmaceuticals Inc. is looking more favorable than Sangamo Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 0% of Agios Pharmaceuticals Inc. shares and 66% of Sangamo Therapeutics Inc. shares. Insiders held roughly 0.3% of Agios Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 0.1% of Sangamo Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 8.26% 25.93% -1.33% -15% -17.41% 46.39%
Sangamo Therapeutics Inc. 11.74% -13.69% -15.42% -39.94% -57.06% -12.11%

For the past year Agios Pharmaceuticals Inc. has 46.39% stronger performance while Sangamo Therapeutics Inc. has -12.11% weaker performance.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.